Free Trial
NASDAQ:ZYXI

Zynex Q2 2025 Earnings Report

Zynex logo
$2.72 +0.12 (+4.41%)
As of 02:01 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Zynex EPS Results

Actual EPS
N/A
Consensus EPS
-$0.20
Beat/Miss
N/A
One Year Ago EPS
N/A

Zynex Revenue Results

Actual Revenue
N/A
Expected Revenue
$27.38 million
Beat/Miss
N/A
YoY Revenue Growth
N/A

Zynex Announcement Details

Quarter
Q2 2025
Time
Before Market Opens
Conference Call Date
Thursday, July 24, 2025
Conference Call Time
4:15PM ET

Conference Call Resources

Zynex Earnings Headlines

Zynex awarded UK patent for non-invasive sepsis monitoring technology
We’ve Entered the Most Bullish Phase of the Cycle
It happens like clockwork. Every four years, the crypto market enters a new phase — and for those who know how to trade it, this phase brings the most potential. We’re now in that window. A free workshop outlines how a proven system is targeting daily wins, passive income, and explosive upside through curated altcoin picks. Whether you're new to crypto or looking to catch the next move with confidence, this is your roadmap. And just for showing up, you’ll receive $10 in real Bitcoin. Don’t miss it.
Zynex Announces Workforce Reduction
Here’s Why Zynex (ZYXI) Fell in Q1
See More Zynex Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Zynex? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Zynex and other key companies, straight to your email.

About Zynex

Zynex (NASDAQ:ZYXI), Inc., together with its subsidiaries, designs, manufactures, and markets medical devices to treat chronic and acute pain; and activate and exercise muscles for rehabilitative purposes with electrical stimulation. The company offers NexWave, a dual channel, multi-modality interferential current, transcutaneous electrical nerve stimulation, and neuromuscular electrical stimulation (NMES) device that is marketed to physicians and therapists by field sales representatives; NeuroMove, an electromyography and electric stimulation technology device; InWave, an electrical stimulation product for the treatment of female urinary incontinence; E-Wave, an NMES device; M-Wave, an NMES device. It also supplies private labeled products, including electrodes for the delivery of electrical current to the body, and batteries for use in electrotherapy products. In addition, the company distributes Comfortrac/Saunders for cervical traction, JetStream for hot/cold therapy, LSO Back Braces for lumbar support, and braces for rehabilitation support. Further, it offers Zynex Fluid Monitoring System (CM-1500); Zynex Wireless Fluid Monitoring System (CM-1600), a noninvasive monitoring device designed to measure relative changes in fluid volume in adult patients; NiCO CO-Oximeter, a laser-based noninvasive co-oximeter; and HemeOx tHb Oximeter, a laser-based total hemoglobin pulse oximeter. The company provides its products for use in pain management and control; stroke and spinal cord injury rehabilitation; hemodynamic monitoring and intravascular volume monitoring; and pulse oximetry monitoring. It sells its products through direct sales force primarily in the United States. Zynex, Inc. was founded in 1996 and is headquartered in Englewood, Colorado.

View Zynex Profile

More Earnings Resources from MarketBeat